Paracetamol

Introduction Overview

Generic Name

paracetamol

Brand Name

Panadol, Calpol, Tylenol, Alvedon

Dosage Form

effervescent tablet, intravenous (infusion) injection, orally disintegrating tablet, oral capsule, oral powder, oral suspension, oral tablet, suppository

Drug Class

Miscellaneous analgesics

Pharmacokinetics

Absorption:
Paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract after oral administration. Its absorption primarily occurs in the small intestine, with minor absorption in the stomach. Peak plasma concentrations are typically reached within 30 to 60 minutes following oral dosing. The rate and extent of absorption can be influenced by factors such as gastric emptying time and the specific formulation used (e.g., immediate-release tablets vs effervescent tablets). Intravenous administration provides 100% bioavailability, with rapid distribution into systemic circulation.

Distribution:
Paracetamol demonstrates a volume of distribution approximating 0.9 L/kg, indicating widespread distribution throughout total body water. It is moderately bound to plasma proteins, with binding ranging from 10% to 25%, which tends to be concentration-independent at therapeutic levels. It readily crosses the blood-brain barrier, which is significant for its central analgesic and antipyretic effects. Paracetamol also crosses the placenta and is found in breast milk at low concentrations.

Metabolism:
The drug undergoes extensive hepatic metabolism primarily via conjugation with glucuronide (approximately 55%) and sulfate (about 30-40%) pathways to inactive metabolites. A minor fraction (about 5-10%) is metabolized by the cytochrome P450 enzyme system, mainly isoform CYP2E1, producing a reactive intermediate metabolite, N-acetyl-p-benzoquinone imine (NAPQI). Under normal circumstances, NAPQI is swiftly detoxified by hepatic glutathione conjugation, preventing toxicity. However, in overdose situations, glutathione stores become depleted, leading to accumulation of NAPQI and consequent hepatocellular injury.

Elimination:
Paracetamol and its inactive metabolites are primarily eliminated via renal excretion. The elimination half-life is approximately 1.5 to 3 hours in healthy adults, although this may be prolonged in hepatic impairment or overdose. The majority of the dose is excreted in urine within 24 hours as conjugated metabolites. Small amounts of unchanged paracetamol are also excreted in urine. Renal clearance can be affected by factors such as age, renal function, and co-administration of enzyme-inducing drugs.

Overall, paracetamol demonstrates predictable pharmacokinetics that enable flexible dosing regimens in various populations, but care must be taken in patients with liver or kidney dysfunction due to altered metabolism and elimination.

Dosage Forms

Available Dosage Forms:
- Oral tablet (standard formulations, e.g., 500 mg)
- Effervescent tablets (e.g., 500 mg)
- Orally disintegrating tablets (250 mg)
- Oral capsules (500 mg)
- Oral powder (650 mg sachets for solution)
- Oral suspensions (120 mg/5 mL and 250 mg/5 mL)
- Suppositories (60 mg, 125 mg, 250 mg)
- Intravenous (IV) solution for infusion (10 mg/mL)

Dosages for Adults and Adolescents:
- Oral tablets/capsules: Adults and children over 16 years: 1 to 2 tablets (500 mg each) every 4 to 6 hours as needed, not to exceed 8 tablets (4 g) within 24 hours.
- Effervescent tablets: 1 to 2 tablets (500 mg) dissolved in water every 4 to 6 hours, maximum 8 tablets daily.
- Orally disintegrating tablets: Adults and children over 16 years: 2 to 4 tablets (250 mg each) every 4 to 6 hours, up to 4 times daily.
- Oral suspension (250 mg/5 mL): Adults and children 6 years and older, 10 to 20 mL every 4 to 6 hours.
- Oral suspension (120 mg/5 mL): Dosing varies by weight and age in children from 2 months up to 16 years, with doses ranging from 2.5 mL up to 15 mL given up to 4 times daily.
- Oral powder: Adults and children over 12 years: 1 sachet (650 mg) dissolved in water every 4 hours, maximum 4 sachets daily.
- Suppositories: Doses vary with age from 60 mg in infants up to 250 mg in older children, administered every 4 to 6 hours, with maximum daily doses aligned to age and weight.
- Intravenous infusion (10 mg/mL): Doses calculated based on weight, age, and renal function, typically administered over 15 minutes.

Specific Patient Populations:
- Pediatric dosing is weight and age-specific, with careful instructions on the use of oral suspensions and suppositories to prevent toxicity.
- Use in hepatic or renal impairment requires cautious dosing, often reducing frequency or dose to prevent accumulation.
- Intravenous form primarily used in hospitalized patients when oral administration is not feasible.
- Pregnant and breastfeeding women can use paracetamol at the lowest effective dose for the shortest duration.

Clinical guidelines emphasize not exceeding 4 grams per day in adults, recognizing increased risk of hepatotoxicity with higher doses, chronic use, or concomitant alcohol use. Pediatric dosing must be strictly followed according to age and weight, with appropriate measuring devices to ensure accuracy.

Mechanism Of Action

Paracetamol exerts its analgesic and antipyretic effects primarily through central nervous system mechanisms, although the exact molecular pathways remain incompletely understood. It is thought to inhibit the enzyme cyclooxygenase (COX), particularly a COX isoform variant distinct from COX-1 and COX-2, often referred to as COX-3 in the brain, leading to reduced synthesis of prostaglandins, which mediate pain and fever.

Unlike nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol lacks significant peripheral anti-inflammatory effects due to negligible inhibition of COX enzymes in peripheral tissues. This central selectivity explains its efficacy in pain relief and fever reduction without marked gastrointestinal or platelet-related side effects.

Additionally, paracetamol modulates other neurotransmitter systems including serotonergic pathways, enhancing descending inhibitory pain signals in the spinal cord. It also appears to activate cannabinoid receptors and may involve nitric oxide synthase pathways, contributing to its analgesic effect. Some evidence suggests engagement of the endogenous opioid system, indirectly augmenting pain inhibition.

Clinically, these mechanisms result in the effective treatment of mild-to-moderate pain such as headache, musculoskeletal pain, dental pain, and reduction of fever, without the typical adverse effects associated with NSAIDs or opioids. Comparative studies have shown paracetamol’s analgesic efficacy is comparable to low-dose NSAIDs but with superior gastrointestinal safety and negligible effects on platelet function. Ongoing research continues to elucidate its complex pharmacodynamics, including potential neuroprotective roles and benefits in combination analgesia.

Pharmacological Actions

Analgesic action by central inhibition of prostaglandin synthesis.
Antipyretic effect mediated through hypothalamic heat-regulating centers.
Minimal anti-inflammatory activity due to limited peripheral COX inhibition.
Modulation of serotonergic descending pain inhibitory pathways.
Indirect activation of endogenous cannabinoid receptors involved in pain modulation.
Possible interaction with nitric oxide pathways contributing to analgesic effects.
Lack of significant platelet aggregation inhibition or gastrointestinal irritation.
Rapid onset and short duration of action when administered orally or intravenously.
Good safety profile at recommended doses with minimal adverse effects.
Compatibility with various formulation types for diverse clinical needs.

Therapeutic Or Clinical Uses

Management of mild-to-moderate pain including headache, migraine, and tension-type headache.
Relief of musculoskeletal pains such as backache, muscle aches, and osteoarthritis.
Treatment of dental pain and post-operative pain relief.
Reduction of fever (antipyresis) in infectious and non-infectious conditions.
Alleviation of dysmenorrhea (period pain).
Symptomatic treatment in cold and flu, including sore throat and sinus pain.
Safe analgesic option in pediatric populations, including infants with appropriate dosing.
Adjunct analgesic in multimodal pain management strategies.
Use in patients with contraindications to NSAIDs or aspirin due to safer profile.
Supportive care in palliative and chronic pain management.

Side Or Adverse Effects

Rare but serious allergic reactions including skin rash, hives, and anaphylaxis.
Skin reactions such as Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis in rare cases.
Liver toxicity with overdose or prolonged high-dose usage, potentially leading to acute liver failure.
Nausea, vomiting, and abdominal pain as early signs of acute overdose.
Potential renal impairment with chronic high-dose use.
Redness or soreness in or around the rectum with suppository use.
Hypersensitivity reactions including swelling of the face, tongue, or throat.
Rare hematologic abnormalities such as thrombocytopenia or leukopenia.
Potential for metabolic acidosis especially in cases of overdose or in individuals with sepsis or malnutrition.
Minimal gastrointestinal irritation compared to NSAIDs.
Possible exacerbation of asthma symptoms in sensitive individuals, though less common than aspirin.
Common adverse effects rarely reported at therapeutic doses, highlighting the drug’s high tolerability.

Precautions

Avoid exceeding the recommended maximum daily dose to prevent hepatotoxicity.
Use with caution in patients with pre-existing liver disease or severe hepatic impairment.
Monitor patients with renal impairment for accumulation and toxicity risk.
Avoid concomitant use of multiple paracetamol-containing products to prevent inadvertent overdose.
Careful dosing in malnourished or underweight patients due to increased toxicity risk.
Alcohol consumption increases the risk of liver damage, so caution or avoidance advised.
Use with caution in individuals with glucose-6-phosphate dehydrogenase deficiency or hemolytic anemia.
Monitor for signs of allergic reactions or skin rash during treatment.
Avoid prolonged use beyond 3 days without medical supervision.
Advise caregivers about proper dosing and measuring instruments, especially in pediatric patients.
Caution in patients with asthma, especially if sensitive to aspirin or other NSAIDs.
In patients with severe infection, watch for metabolic acidosis symptoms, which may warrant limiting paracetamol use.

Warnings

Risk of severe hepatotoxicity and acute liver failure after overdose, which may be fatal.
Do not use in combination with other paracetamol-containing medications to avoid unintentional overdose.
Potential for serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Immediate medical attention required if signs of allergic reaction such as facial swelling or breathing difficulties occur.
Careful monitoring in patients with chronic alcohol use due to heightened toxicity risk.
Avoid use in children under 2 months without medical advice.
Metabolic acidosis from toxic metabolites can develop, particularly in malnutrition, sepsis, renal impairment, or chronic alcoholism.
Caution advised during pregnancy and breastfeeding; use lowest effective dose for shortest duration.
Potential interactions with certain antibiotics, anticonvulsants, and other medications necessitate medical consultation.
Keep out of reach of children; accidental overdose is a medical emergency.
Storage instructions to prevent degradation and maintain efficacy must be followed strictly.
IV paracetamol administration requires healthcare provider dosing calculation and supervision.

Contraindication

Known hypersensitivity or allergy to paracetamol or any components of the formulation.
Severe hepatic impairment or active liver disease.
Use of paracetamol-containing products concurrently leading to potential overdose.
Children under 2 months of age without medical supervision.
Known severe allergic reactions to paracetamol such as anaphylaxis.
Patients with a history of severe skin reactions linked to paracetamol.
Caution in patients with rare enzyme disorders like glucose-6-phosphate dehydrogenase deficiency.
Avoid in patients with acute or chronic metabolic acidosis without medical clearance.
Contraindicated in patients with unexplained bruising, bleeding disorders without consultation.
Use contraindicated when accurate dosing cannot be ensured (e.g., due to swallowing difficulties with oral forms in absence of alternatives).

Drug Interactions

Warfarin and other anticoagulants: chronic high-dose use may potentiate anticoagulant effects and increase bleeding risk.
Metoclopramide and domperidone: may increase the rate of paracetamol absorption.
Cholestyramine: may reduce paracetamol absorption if administered concurrently.
Lamotrigine: co-administration can alter metabolism of one or both drugs.
Isoniazid and other enzyme-inducing drugs: may enhance hepatotoxic risk by increasing formation of toxic metabolites.
Aspirin and salicylamides: concurrent use can increase risk of toxicity, especially hepatic.
Barbiturates and tricyclic antidepressants (e.g., amitriptyline): may induce hepatic enzymes altering paracetamol metabolism.
Probenecid: can affect paracetamol excretion and metabolism.
Chloramphenicol: potential alteration in metabolism warranting caution.
Zidovudine (antiretroviral): potential for increased toxicity.
Flucloxacillin: combined use may lead to high anion gap metabolic acidosis, particularly in renal impairment or malnourished patients.
Oral contraceptives may decrease the efficacy of paracetamol in pain and fever relief.
Paracetamol may interfere with laboratory diagnostic tests such as uric acid and blood glucose measurements.

Preparations Of The Drug

Zentiva paracetamol capsules containing maize starch and magnesium stearate; gelatin capsules colored with titanium dioxide, erythrosine, yellow iron oxide, and indigo carmine.
Panadol original tablets formulated with maize starch, potassium sorbate, purified talc, stearic acid, povidone, pregelatinized starch, hypromellose, triacetin, and carnauba wax.
Effervescent tablets containing anhydrous citric acid, sodium hydrogen carbonate, sorbitol, sodium carbonate anhydrous, povidone K25, simethicone, saccharin sodium, and lemon flavor.
Accord intravenous infusion includes cysteine hydrochloride monohydrate, disodium phosphate dihydrate, pH adjusters hydrochloric and sodium hydroxide, mannitol, and water for injections.
Calpol SixPlus Fastmelts orally disintegrating tablets composed of mannitol, crospovidone, aspartame, magnesium stearate, methacrylate copolymers, polyacrylate dispersion, colloidal silica, and strawberry flavor containing benzyl alcohol and glucose.
Boots Cold & Flu Relief Powders with sucrose, sodium citrate, citric acid, tartaric acid, sodium cyclamate, ascorbic acid, starch, natural colorant (E100), spray dried lemon juice, and lemon aroma.
Calpol infant oral suspension contains sucrose, sorbitol liquid, glycerol, polysorbate 80, potassium asulfame, methyl, propyl, and ethyl parahydroxybenzoates, microcrystalline cellulose, carmellose sodium, xanthan gum, purified water, strawberry flavor, propylene glycol, and carmoisine coloring.
Alvedon paracetamol suppositories utilize hard fat (Witepsol H12) as the base.
Various generic and branded formulations with differing excipient profiles for tablets, suspensions, and suppositories catering to specific patient needs.
All preparations maintain the active ingredient's stability and bioavailability while ensuring patient acceptability, palatability, and ease of administration.